Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Net Income (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Net Income for 6 consecutive years, with -$14.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Income fell 79.25% year-over-year to -$14.6 million, compared with a TTM value of -$75.9 million through Sep 2025, down 31.21%, and an annual FY2024 reading of -$61.2 million, up 16.7% over the prior year.
  • Net Income was -$14.6 million for Q3 2025 at Barinthus Biotherapeutics, up from -$21.1 million in the prior quarter.
  • Across five years, Net Income topped out at $15.7 million in Q2 2022 and bottomed at -$23.8 million in Q2 2023.
  • Average Net Income over 5 years is -$12.2 million, with a median of -$16.8 million recorded in 2021.
  • The sharpest move saw Net Income soared 261.58% in 2022, then tumbled 1294.17% in 2023.
  • Year by year, Net Income stood at -$16.8 million in 2021, then dropped by 25.69% to -$21.2 million in 2022, then rose by 18.3% to -$17.3 million in 2023, then dropped by 19.09% to -$20.6 million in 2024, then grew by 29.24% to -$14.6 million in 2025.
  • Business Quant data shows Net Income for BRNS at -$14.6 million in Q3 2025, -$21.1 million in Q2 2025, and -$19.7 million in Q1 2025.